Results 221 to 230 of about 677,625 (318)

Topical betulinic acid for treatment of equine melanoma and sarcoid. [PDF]

Front Vet Sci
Moreno C, Mudge M, Horne R, Yardley J.
europepmc   +1 more source

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh, Kate Hanrott, Olof Breuer, Johan Bylund, Björn Schultze, Virginia Norris   +5 more
wiley   +1 more source

GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA Psychiatry
Cubala WJ, Bajbouj M, Bauer M, Baune BT, Cardoner N, Devlin F, Doolin K, Dueñas Herrero RM, Elices M, Feeney A, Galuszko-Wegielnik M, Jakuszkowiak-Wojten K, Janu L, Kelly JR, Ledden K, Maclsaac R, Madero S, McInerney SJ, Montejo AL, Nawka A, Pálenícek T, Pérez Solà V, Ramaekers JG, Reif A, Ritter P, Ryan F, Svendsen CB, Sweeney C, Terwey TH, Trivedi MH, Valcheva V, Vieta E, Thase ME.   +32 more
europepmc   +1 more source

The Efficacy of Nicotinamide in Maintaining Mean Deviation in Glaucoma: A Systematic Review. [PDF]

Cureus
Sherratt-Mayhew S, Bisp M, Page C, Koo WSV.   +3 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Curcumin versus placebo in benign prostatic hyperplasia: a systematic review and meta-analysis. [PDF]

Eur J Clin Pharmacol
Santana DS, Porto BC, Cardoso RB, Lopes GMM, Gimenez LGS, Passerotti CC, Maia R, Almeida FG, da Silva Sardenberg RA, da Cruz JAS.   +9 more
europepmc   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source

Efficacy and safety of DMB-I (latrepirdine) therapy in mild to moderate dementia in Alzheimer's disease: results of a multicenter, double-blind, randomized, placebo-controlled, clinical trial in three parallel groups. [PDF]

Sci Rep
Gorin BI, Pozdnyakov SO, Potapova KA, Tukhovskaya EA, Gorchakov DS.   +4 more
europepmc   +1 more source

Psychotropic medication use among community dwellers with and without Parkinson's disease – A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen, Anna‐Maija Tolppanen, Valtteri Kaasinen, Marjaana Koponen, Sirpa Hartikainen   +4 more
wiley   +1 more source

Correction: Rosmagain™ as a Natural Therapeutic for Hair Regrowth and Scalp Health: A Double-Blind, Randomized, Three-Armed, Placebo-Controlled Clinical Trial. [PDF]

Cureus
Patel MN, Tuli N, Patel N, Merja A.
europepmc   +1 more source